NICE approves euthanrhus anti-inflammatory drug Cimzia (certolizumab pegol) for treatment of adult patients with plaque psoriasis
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the National Institute scare spree (NICE) approved the UCB anti-inflammatory drug Cimzia (certolizumab pegol) for the treatment of adult patients with severe plaque psoriasis who have no response to other systemic therapies or are not suitableAbout Cimzia
Cimzia is a biological agent that effectively prevents inflammation caused by overactivation of the immune systemPreviously, NICE has approved Cimzia for the treatment of moderate to severe active rheumatoid arthritis (RA) that has previously been treated with a TNF inhibitor, active psoriasis arthritis (PsA), severe active spinal arthritis (AS) that has been treated with a TNF inhibitor, and severe non-radiation spinal arthritis (n)Cimzia is the only anti-tumor necrosis factor alpha (TNF-alpha) withnosing fc domain, polyglycol-modified modification,drug(http://, has a very high affinity for human TNF-alpha, and is able to selectively and tNF-alpha."So far, Cimzia has been approved by many countries and regions around the world for the treatment of a variety of inflammatory diseases, including rheumatoid arthritis, psoriasis arthritis, stoic syllritis, spinal arthritis, Crohn's disease, etcAt the end of March, Cimzia was approved by the U.SFDA(http://for the treatment of adult patients with active non-radiative non-radiative axial spinal arthritis (nr-axSpA) with inflammatory signsthis approval, making Cimzia the first and only drug to receive FDA approval to treat nr-axSpA
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
